Business
Cardiol Therapeutics at the Intersection of Pharmaceutical CBD and Biotech, Plus Exclusive CEO Interview -- CFN Media
Seattle, Washington--(Newsfile Corp. - May 7, 2019) - CFN Media Group ("CFN Media"), the leadi...
About this update from Cardiol Therapeutics Inc. Class A
[{"type":"text","content":"Cardiol Therapeutics at the Intersection of Pharmaceutical CBD and Biotech, Plus Exclusive CEO Interview -- CFN MediaSeattle, Washington--(Newsfile Corp. - May 7, 2019) - CFN Media Group (\"CFN Media\"), the leading agency and financial media network dedicated to the North American cannabis industry, announces the publication of an article and exclusive CEO video interview covering Cardiol Therapeutics Inc. (Cardiol) (TSX: CRDL) (OTC Pink: CRTPF), its development of cannabidiol (CBD) based drugs, and its plan to launch a commercial pharmaceutical CBD oil product. Historically, the biotech sector has offered high returns on investment as drug candidates make their way through the clinical trials process toward a potential approval. Currently, there is plenty of buzz around the emergent legal cannabis sector as a place where high returns can be found. Both industries present pitfalls as well, with poorly-run companies scattered along the way. The trick is finding the most competent companies. Cardiol Therapeutics, led by an executive team with plenty of relevant experience and success, sits squarely at the intersection of the cannabis and biotech sectors. Cardiol is a serious drug-development company looking for treatments for heart disease and brain cancer. The company's researchers believe that cannabidiol (CBD), a non-psychoactive cannabinoid from the cannabis plant, may help to treat these serious conditions. In the course of sourcing pure CBD for its research, Cardiol recognized a shortage of CBD in the legal medical cannabis market and will soon launch a commercial pharmaceutical CBD product. The company has created supply partnerships for this unique pure CBD product which allow them the capacity to commercialize large volumes of pure pharmaceutical CBD in the supply-constrained market.Cardiol has the opportunity to expand into two of the highest growth sectors in today's market.Click here to see Cardiol's presentation and receive corporate updates.CFN Media recently caught up with Cardiol Therapeutics' President and CEO, David Elsley. Mr. Elsley discusses Cardiol's approach to CBD drug development and its strategy for the CardiolRx pharmaceutical CBD rollout. Please follow this link to see the interview on CannabisFN: https://www.cannabisfn.com/cfnvideo/?id=xxBK1w3dPharmaceutical CBDA very compelling aspect of Cardiol's st...